JP6374889B2 - β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 - Google Patents
β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 Download PDFInfo
- Publication number
- JP6374889B2 JP6374889B2 JP2015561682A JP2015561682A JP6374889B2 JP 6374889 B2 JP6374889 B2 JP 6374889B2 JP 2015561682 A JP2015561682 A JP 2015561682A JP 2015561682 A JP2015561682 A JP 2015561682A JP 6374889 B2 JP6374889 B2 JP 6374889B2
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- oxa
- independently
- pharmaceutically acceptable
- hept
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(*)(C12*)C1(*)OC(N)=NC2(*)C1=*C(*)=*[*+]1 Chemical compound *C(*)(C12*)C1(*)OC(N)=NC2(*)C1=*C(*)=*[*+]1 0.000 description 18
- SQEJJKZVOKBGOC-UHFFFAOYSA-N FCC1=NOC2C1C2 Chemical compound FCC1=NOC2C1C2 SQEJJKZVOKBGOC-UHFFFAOYSA-N 0.000 description 2
- UISBKVAXCCPZLU-UHFFFAOYSA-N C#CCOc1ccc(C(O)=O)nc1 Chemical compound C#CCOc1ccc(C(O)=O)nc1 UISBKVAXCCPZLU-UHFFFAOYSA-N 0.000 description 1
- RMYQHHAMJSRPFF-UHFFFAOYSA-N CC#Cc1c[nH]nc1 Chemical compound CC#Cc1c[nH]nc1 RMYQHHAMJSRPFF-UHFFFAOYSA-N 0.000 description 1
- BJSNEMLQKRVUTF-CMPLNLGQSA-N CC(C)([C@@H](C1)[C@@H]1O)c1c(C)c(F)ccc1 Chemical compound CC(C)([C@@H](C1)[C@@H]1O)c1c(C)c(F)ccc1 BJSNEMLQKRVUTF-CMPLNLGQSA-N 0.000 description 1
- CLHGOEZCXVAKDZ-UHFFFAOYSA-N CC(c1nc(C(O)=O)c[o]1)F Chemical compound CC(c1nc(C(O)=O)c[o]1)F CLHGOEZCXVAKDZ-UHFFFAOYSA-N 0.000 description 1
- SXUAEWDKXQVDOA-JENMUQSASA-N CC[C@]1(c2c(C)c(F)ccc2)N=C(C)O[C@H]2C1C2 Chemical compound CC[C@]1(c2c(C)c(F)ccc2)N=C(C)O[C@H]2C1C2 SXUAEWDKXQVDOA-JENMUQSASA-N 0.000 description 1
- ZIRPEVXBEZKGKY-UHFFFAOYSA-N COc1c(C(O)=O)ncc(Cl)c1 Chemical compound COc1c(C(O)=O)ncc(Cl)c1 ZIRPEVXBEZKGKY-UHFFFAOYSA-N 0.000 description 1
- XZYMYAWZLXRXCR-UHFFFAOYSA-N COc1cnc2c(Cl)nccc2c1 Chemical compound COc1cnc2c(Cl)nccc2c1 XZYMYAWZLXRXCR-UHFFFAOYSA-N 0.000 description 1
- MQYSEKKJECGRMS-QEIKUCIBSA-N C[C@]1(c(cccc2F)c2F)N=C(C)OC2C1C2 Chemical compound C[C@]1(c(cccc2F)c2F)N=C(C)OC2C1C2 MQYSEKKJECGRMS-QEIKUCIBSA-N 0.000 description 1
- RJCXWKYQQJRQBN-MOBVGWBASA-N C[C@]1(c(cccc2F)c2F)NO[C@H]2C1C2 Chemical compound C[C@]1(c(cccc2F)c2F)NO[C@H]2C1C2 RJCXWKYQQJRQBN-MOBVGWBASA-N 0.000 description 1
- KFEOUDDLCXBGOS-PESDSKBTSA-N C[C@]1(c2c(C)c(F)cc(C)c2)N=C(C)OC2C1C2 Chemical compound C[C@]1(c2c(C)c(F)cc(C)c2)N=C(C)OC2C1C2 KFEOUDDLCXBGOS-PESDSKBTSA-N 0.000 description 1
- KFEOUDDLCXBGOS-NWANDNLSSA-N C[C@]1(c2c(C)c(F)cc(C)c2)N=C(C)O[C@H]2[C@@H]1C2 Chemical compound C[C@]1(c2c(C)c(F)cc(C)c2)N=C(C)O[C@H]2[C@@H]1C2 KFEOUDDLCXBGOS-NWANDNLSSA-N 0.000 description 1
- JEEPOINHZLHULS-PCJJGOFDSA-N C[C@]1(c2nc(NC(c(nc3)ccc3C#N)=O)ccc2F)[Ar]=C(N)O[C@H]2[C@@H]1C2 Chemical compound C[C@]1(c2nc(NC(c(nc3)ccc3C#N)=O)ccc2F)[Ar]=C(N)O[C@H]2[C@@H]1C2 JEEPOINHZLHULS-PCJJGOFDSA-N 0.000 description 1
- HUMKSYLKBZQSFQ-VRBQQETQSA-N FC[C@]1(c(nc(cc2)Cl)c2F)NOC2[C@@H]1C2 Chemical compound FC[C@]1(c(nc(cc2)Cl)c2F)NOC2[C@@H]1C2 HUMKSYLKBZQSFQ-VRBQQETQSA-N 0.000 description 1
- VURFKVWVLLJDIC-UHFFFAOYSA-N N#Cc(cnc1c(nc2)Cl)cc1c2F Chemical compound N#Cc(cnc1c(nc2)Cl)cc1c2F VURFKVWVLLJDIC-UHFFFAOYSA-N 0.000 description 1
- VEPZLCHNICQZEA-UHFFFAOYSA-N N#Cc1cnc(C(O)=O)nc1 Chemical compound N#Cc1cnc(C(O)=O)nc1 VEPZLCHNICQZEA-UHFFFAOYSA-N 0.000 description 1
- KYGGDRMUMYLCCU-UHFFFAOYSA-N OC(c1c[o]c(C#CC2CC2)n1)=O Chemical compound OC(c1c[o]c(C#CC2CC2)n1)=O KYGGDRMUMYLCCU-UHFFFAOYSA-N 0.000 description 1
- MKLFNFRBDNMKIU-UHFFFAOYSA-N OC(c1ccc(C(F)F)cn1)=O Chemical compound OC(c1ccc(C(F)F)cn1)=O MKLFNFRBDNMKIU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775380P | 2013-03-08 | 2013-03-08 | |
| US61/775,380 | 2013-03-08 | ||
| US201461939580P | 2014-02-13 | 2014-02-13 | |
| US61/939,580 | 2014-02-13 | ||
| PCT/US2014/021412 WO2014138484A1 (en) | 2013-03-08 | 2014-03-06 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510758A JP2016510758A (ja) | 2016-04-11 |
| JP2016510758A5 JP2016510758A5 (OSRAM) | 2017-04-06 |
| JP6374889B2 true JP6374889B2 (ja) | 2018-08-15 |
Family
ID=50478936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561682A Active JP6374889B2 (ja) | 2013-03-08 | 2014-03-06 | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9085576B2 (OSRAM) |
| EP (1) | EP2964644B1 (OSRAM) |
| JP (1) | JP6374889B2 (OSRAM) |
| KR (1) | KR20150124985A (OSRAM) |
| CN (1) | CN105164121A (OSRAM) |
| AP (1) | AP2015008716A0 (OSRAM) |
| AU (1) | AU2014225604B2 (OSRAM) |
| BR (1) | BR112015021336A2 (OSRAM) |
| CA (1) | CA2903215C (OSRAM) |
| CL (1) | CL2015002516A1 (OSRAM) |
| CR (1) | CR20150519A (OSRAM) |
| EA (1) | EA201591614A1 (OSRAM) |
| HK (1) | HK1217486A1 (OSRAM) |
| IL (1) | IL240829A0 (OSRAM) |
| MX (1) | MX374512B (OSRAM) |
| PE (1) | PE20151794A1 (OSRAM) |
| PH (1) | PH12015502001A1 (OSRAM) |
| SG (1) | SG11201507196WA (OSRAM) |
| TN (1) | TN2015000382A1 (OSRAM) |
| TW (1) | TW201446760A (OSRAM) |
| UY (1) | UY35377A (OSRAM) |
| WO (1) | WO2014138484A1 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010013256A (es) | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| KR20150124985A (ko) | 2013-03-08 | 2015-11-06 | 암젠 인크 | 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법 |
| SG11201507411TA (en) | 2013-03-13 | 2015-10-29 | Astellas Pharma Inc | Guanidinobenzoic acid ester compound |
| US9346776B2 (en) | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AU2015301028B2 (en) | 2014-08-08 | 2019-09-26 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| US9868738B2 (en) * | 2014-09-19 | 2018-01-16 | Merck Sharp & Dohme Corp. | Diazine-fused amidines as BACE inhibitors, compositions, and their use |
| WO2016118404A1 (en) * | 2015-01-20 | 2016-07-28 | Merck Sharp & Dohme Corp. | Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use |
| WO2016179460A1 (en) | 2015-05-07 | 2016-11-10 | Bristol-Myers Squibb Company | Tricyclic sulfones as rorϒ modulators |
| JP6913076B2 (ja) * | 2015-08-07 | 2021-08-04 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 有害生物防除剤としての２−（ヘタ）アリール−置換縮合ヘテロ環誘導体 |
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| EP3165093A1 (en) | 2015-11-05 | 2017-05-10 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
| MY199220A (en) | 2015-11-19 | 2023-10-20 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) * | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| JP6911031B2 (ja) * | 2015-12-22 | 2021-07-28 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | 免疫調節剤としての複素環化合物 |
| TW201808950A (zh) | 2016-05-06 | 2018-03-16 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MY197280A (en) | 2016-06-20 | 2023-06-09 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MA46045A (fr) | 2016-08-29 | 2021-04-28 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| CN106432071B (zh) * | 2016-09-05 | 2019-04-02 | 河北正朗制药有限公司 | 5-氰基-4-甲氧基-2-吡啶甲酸的盐酸盐的制备及其应用 |
| JP2019529522A (ja) | 2016-10-10 | 2019-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子としての三環式スルホン類 |
| MX394391B (es) | 2016-12-15 | 2025-03-24 | Amgen Inc | Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso. |
| WO2018112086A1 (en) | 2016-12-15 | 2018-06-21 | Amgen Inc. | Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use |
| AU2017376441B2 (en) * | 2016-12-15 | 2021-10-14 | Amgen Inc. | Oxazine derivatives as beta-secretase inhibitors and methods of use |
| AU2017376444B2 (en) | 2016-12-15 | 2021-09-30 | Amgen Inc. | Thiazine derivatives as beta-secretase inhibitors and methods of use |
| US11021493B2 (en) | 2016-12-15 | 2021-06-01 | Amgen Inc. | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| MA47099A (fr) | 2016-12-22 | 2021-05-12 | Incyte Corp | Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs |
| BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corporation | derivados de benzo-oxazol como imunomoduladores |
| PT3558990T (pt) | 2016-12-22 | 2022-11-21 | Incyte Corp | Derivados de tetrahidroimidazo[4,5-c]piridina como indutores da internalização de pd-l1 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| HRP20230090T1 (hr) | 2018-03-30 | 2023-03-17 | Incyte Corporation | Heterociklički spojevi kao imunomodulatori |
| CA3098430A1 (en) | 2018-04-27 | 2019-10-31 | Shionogi & Co., Ltd. | Tetrahydropyranooxazine derivatives having selective bace1 inhibitory activity |
| HUE061503T2 (hu) | 2018-05-11 | 2023-07-28 | Incyte Corp | Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok |
| CN110759860B (zh) * | 2018-07-27 | 2022-10-14 | 江苏瑞科医药科技有限公司 | 一种3-甲酸甲酯-4-甲氧基-5-氰基吡啶的制备方法 |
| CN109430267A (zh) * | 2018-10-24 | 2019-03-08 | 南京华安药业有限公司 | 一种肟草酮水悬浮剂 |
| CN110183392B (zh) * | 2019-06-14 | 2023-03-28 | 河北医科大学 | 一种3-取代苯基-4，5-二氢异噁唑衍生物的制备方法及其用途和中间体 |
| US11753406B2 (en) | 2019-08-09 | 2023-09-12 | Incyte Corporation | Salts of a PD-1/PD-L1 inhibitor |
| PH12022550754A1 (en) | 2019-09-30 | 2023-08-23 | Incyte Corp | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
| CN110885329B (zh) | 2019-12-16 | 2020-12-15 | 诚达药业股份有限公司 | 一种1,7-萘啶衍生物的合成方法 |
| CN113087669B (zh) * | 2019-12-23 | 2023-11-17 | 南京药石科技股份有限公司 | 一种4-氰基-5-溴嘧啶的制备方法 |
| AU2021267657A1 (en) | 2020-05-05 | 2022-12-08 | Basf Se | Condensed isoxazoline derivatives and their use as herbicides |
| MX2023005362A (es) | 2020-11-06 | 2023-06-22 | Incyte Corp | Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo. |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| WO2024211836A2 (en) | 2023-04-05 | 2024-10-10 | Moma Therapeutics, Inc. | Semi-saturated bicyclic derivatives and related uses |
| CN118852012A (zh) * | 2024-09-26 | 2024-10-29 | 山东国邦药业有限公司 | 一种高收率的二氟吡唑酸的合成方法 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5441870A (en) | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| SI9300303A (en) | 1993-06-08 | 1994-12-31 | Krka Tovarna Zdravil | Process for isolation of hypolipemic effective substance |
| AU6383396A (en) | 1995-06-07 | 1996-12-30 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| US20040234976A1 (en) | 1998-09-24 | 2004-11-25 | Gurney Mark E. | Alzheimer's disease secretase, app substrates therefor, and uses therefor |
| HK1042730B (zh) | 1998-09-24 | 2005-11-18 | 法玛西雅厄普约翰美国公司 | 阿尔茨海默氏疾病分泌酶 |
| EP2153832B1 (en) | 2003-12-15 | 2016-03-09 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| KR101052122B1 (ko) | 2005-10-25 | 2011-07-26 | 시오노기세야쿠 가부시키가이샤 | 아미노디히드로티아진 유도체 |
| WO2008062739A1 (en) | 2006-11-20 | 2008-05-29 | Japan Tobacco Inc. | Pyrazoles and use thereof as drugs |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP2147914B1 (en) | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| US20100317850A1 (en) | 2008-01-18 | 2010-12-16 | Yuichi Suzuki | Condensed aminodihydrothiazine derivative |
| TWI431004B (zh) | 2008-05-02 | 2014-03-21 | Lilly Co Eli | Ｂａｃｅ抑制劑 |
| MX2010013256A (es) | 2008-06-13 | 2010-12-21 | Shionogi & Co | Derivado heterociclico que contiene azufre que tiene actividad inhibitoria de beta-secretasa. |
| AU2009277485B2 (en) | 2008-07-28 | 2013-05-02 | Eisai R&D Management Co., Ltd. | Spiroaminodihydrothiazine derivatives |
| WO2010013302A1 (ja) | 2008-07-28 | 2010-02-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スピロアミノジヒドロチアジン誘導体 |
| US8461160B2 (en) | 2009-05-08 | 2013-06-11 | Hoffmann-La Roche, Inc. | Dihydropyrimidinones |
| AR077277A1 (es) | 2009-07-09 | 2011-08-17 | Lilly Co Eli | Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer |
| GB0912778D0 (en) | 2009-07-22 | 2009-08-26 | Eisai London Res Lab Ltd | Fused aminodihydro-oxazine derivatives |
| US8188079B2 (en) | 2009-08-19 | 2012-05-29 | Hoffman-La Roche Inc. | 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| JPWO2011058763A1 (ja) | 2009-11-13 | 2013-03-28 | 塩野義製薬株式会社 | アミノリンカーを有するアミノチアジンまたはアミノオキサジン誘導体 |
| WO2011070781A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 置換アミノチアジン誘導体 |
| WO2011071057A1 (ja) | 2009-12-09 | 2011-06-16 | 塩野義製薬株式会社 | 含硫黄複素環誘導体を含有するアルツハイマー症の治療用または予防用医薬組成物 |
| US7964594B1 (en) | 2009-12-10 | 2011-06-21 | Hoffmann-La Roche Inc. | Amino oxazine derivatives |
| JPWO2011071109A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | アミノ基を有する縮合ヘテロ環化合物 |
| UA103272C2 (uk) | 2009-12-11 | 2013-09-25 | Ф. Хоффманн-Ля Рош Аг | 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2 |
| JPWO2011071135A1 (ja) | 2009-12-11 | 2013-04-22 | 塩野義製薬株式会社 | オキサジン誘導体 |
| US8673894B2 (en) * | 2010-05-07 | 2014-03-18 | Hoffmann-La Roche Inc. | 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds |
| JP2014505688A (ja) | 2011-01-12 | 2014-03-06 | ノバルティス アーゲー | オキサジン誘導体および神経障害の処置におけるその使用 |
| EP2663308A1 (en) | 2011-01-13 | 2013-11-20 | Novartis AG | Bace-2 inhibitors for the treatment of metabolic disorders |
| US8404680B2 (en) | 2011-02-08 | 2013-03-26 | Hoffmann-La Roche Inc. | N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors |
| US9221839B2 (en) | 2011-04-07 | 2015-12-29 | Merck Sharp & Dohme Corp. | C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| US8754075B2 (en) | 2011-04-11 | 2014-06-17 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE1 and/or BACE2 inhibitors |
| MX2013011947A (es) | 2011-04-13 | 2014-01-16 | Merck Sharp & Dohme | Iminotiazinas 5-sustituidas y sus monoxidos y dioxidos como inhibidores de la enzima que encinde la proteina precursora amiloide en el sitio beta, composiciones y su uso. |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| CN103649082A (zh) | 2011-04-26 | 2014-03-19 | 盐野义制药株式会社 | 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂 |
| US8785436B2 (en) | 2011-05-16 | 2014-07-22 | Hoffmann-La Roche Inc. | 1,3-oxazines as BACE 1 and/or BACE2 inhibitors |
| TW201302763A (zh) | 2011-05-24 | 2013-01-16 | 必治妥美雅史谷比公司 | 用於減少β－類澱粉產生之化合物 |
| US8604024B2 (en) | 2011-05-24 | 2013-12-10 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| US9079919B2 (en) | 2011-05-27 | 2015-07-14 | Hoffmann-La Roche Inc. | Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors |
| JP2012250933A (ja) | 2011-06-03 | 2012-12-20 | Shionogi & Co Ltd | オキサジン誘導体を含有するアルツハイマー症治療用または予防用医薬組成物 |
| AR086653A1 (es) | 2011-06-03 | 2014-01-15 | Bristol Myers Squibb Co | COMPUESTOS PARA LA REDUCCION DE PRODUCCION DE b-AMILOIDE |
| EA023261B1 (ru) | 2011-06-07 | 2016-05-31 | Ф.Хоффманн-Ля Рош Аг | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и(или) bace2 |
| WO2012168175A1 (en) | 2011-06-07 | 2012-12-13 | F. Hoffmann-La Roche Ag | [1,3]oxazines |
| US8927535B2 (en) * | 2011-07-06 | 2015-01-06 | Hoffman-La Roche Inc. | Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors |
| EP2747769B1 (en) | 2011-08-22 | 2017-08-02 | Merck Sharp & Dohme Corp. | 2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use |
| UY34278A (es) | 2011-08-25 | 2013-04-05 | Novartis Ag | Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades |
| EP2751116B1 (en) | 2011-08-31 | 2016-10-12 | Pfizer Inc | Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds |
| US20130073953A1 (en) | 2011-09-21 | 2013-03-21 | Timothy Onyenobi | News headline screenshot viewing system |
| KR20140084146A (ko) | 2011-10-13 | 2014-07-04 | 노파르티스 아게 | 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도 |
| CN103998432A (zh) | 2011-10-24 | 2014-08-20 | 武田药品工业株式会社 | 双环化合物 |
| JP5869151B2 (ja) | 2012-01-26 | 2016-02-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | フルオロメチル−５，６−ジヒドロ−４ｈ−［１，３］オキサジン |
| EP2827857A4 (en) | 2012-03-20 | 2016-03-30 | Elan Pharm Inc | SPIROCYCLIC DIHYDRO-THIAZINE AND INHIBITORS OF BACE DIHYDRO-OXAZINE AND COMPOSITIONS AND USES THEREOF |
| ES2585262T3 (es) | 2012-05-04 | 2016-10-04 | Pfizer Inc | Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2 |
| WO2013182638A1 (en) | 2012-06-08 | 2013-12-12 | H. Lundbeck A/S | 2 -aminothiazinylheteroaryls as bace1 inhibitors for the treatment alzheimer's disease |
| MA37763B1 (fr) | 2012-06-26 | 2017-05-31 | Hoffmann La Roche | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |
| GB201212871D0 (en) | 2012-07-20 | 2012-09-05 | Eisai Ltd | Novel compounds |
| JP2015529239A (ja) | 2012-09-20 | 2015-10-05 | ファイザー・インク | アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物 |
| US9556135B2 (en) | 2012-10-12 | 2017-01-31 | Amgen, Inc. | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use |
| WO2014062553A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| WO2014062549A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| JP2016501827A (ja) * | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| PT2912041T (pt) | 2012-10-26 | 2017-02-13 | Lilly Co Eli | Inibidores de bace |
| EP2931284B1 (en) | 2012-12-14 | 2017-08-23 | Merck Sharp & Dohme Corp. | Bace inhibitors of iminothiadiazine dioxides |
| WO2014098831A1 (en) | 2012-12-19 | 2014-06-26 | Bristol-Myers Squibb Company | 4,6-diarylaminothiazines as bace1 inhibitors and their use for the reduction of beta-amyloid production |
| EP2935282A1 (en) | 2012-12-19 | 2015-10-28 | Pfizer Inc. | CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS |
| EP2934539B1 (en) | 2012-12-20 | 2019-03-27 | Merck Sharp & Dohme Corp. | C5, c6 oxacyclic-fused iminothiazine dioxide compounds as bace inhibitors |
| WO2014099788A1 (en) | 2012-12-21 | 2014-06-26 | Merck Sharp & Dohme Corp. | C5-spiro iminothiadiazine dioxides as bace inhibitors |
| CN104968660A (zh) | 2013-01-22 | 2015-10-07 | 霍夫曼-拉罗奇有限公司 | 作为bace1抑制剂的氟-[1,3]噁嗪类化合物 |
| CA2902212C (en) | 2013-03-01 | 2020-10-13 | Amgen Inc. | Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use |
| KR20150124985A (ko) | 2013-03-08 | 2015-11-06 | 암젠 인크 | 베타-세크레타제 억제제로서 퍼플루오르화된 사이클로프로필 융합된 1,3-옥사진-2-아민 화합물 및 그의 사용 방법 |
| US10263174B2 (en) | 2013-03-15 | 2019-04-16 | Nano Composite Products, Inc. | Composite material used as a strain gauge |
| AU2014253275B2 (en) | 2013-04-11 | 2018-10-18 | F. Hoffmann-La Roche Ag | BACE1 inhibitors |
| HK1213562A1 (zh) | 2013-04-26 | 2016-07-08 | 豪夫迈‧罗氏有限公司 | Bace抑制剂的合成 |
| TW201623295A (zh) | 2014-04-11 | 2016-07-01 | 塩野義製藥股份有限公司 | 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物 |
| AU2015301028B2 (en) | 2014-08-08 | 2019-09-26 | Amgen Inc. | Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use |
-
2014
- 2014-03-06 KR KR1020157026887A patent/KR20150124985A/ko not_active Withdrawn
- 2014-03-06 AU AU2014225604A patent/AU2014225604B2/en active Active
- 2014-03-06 BR BR112015021336A patent/BR112015021336A2/pt not_active IP Right Cessation
- 2014-03-06 AP AP2015008716A patent/AP2015008716A0/xx unknown
- 2014-03-06 CN CN201480013095.9A patent/CN105164121A/zh active Pending
- 2014-03-06 EA EA201591614A patent/EA201591614A1/ru unknown
- 2014-03-06 JP JP2015561682A patent/JP6374889B2/ja active Active
- 2014-03-06 MX MX2015011618A patent/MX374512B/es active IP Right Grant
- 2014-03-06 US US14/199,844 patent/US9085576B2/en active Active
- 2014-03-06 EP EP14717004.7A patent/EP2964644B1/en active Active
- 2014-03-06 WO PCT/US2014/021412 patent/WO2014138484A1/en not_active Ceased
- 2014-03-06 HK HK16105452.2A patent/HK1217486A1/zh unknown
- 2014-03-06 SG SG11201507196WA patent/SG11201507196WA/en unknown
- 2014-03-06 PE PE2015001879A patent/PE20151794A1/es not_active Application Discontinuation
- 2014-03-06 CA CA2903215A patent/CA2903215C/en active Active
- 2014-03-07 TW TW103108045A patent/TW201446760A/zh unknown
- 2014-03-10 UY UY0001035377A patent/UY35377A/es not_active Application Discontinuation
-
2015
- 2015-04-21 US US14/691,715 patent/US20150252011A1/en not_active Abandoned
- 2015-08-25 IL IL240829A patent/IL240829A0/en unknown
- 2015-08-31 TN TN2015000382A patent/TN2015000382A1/en unknown
- 2015-09-08 CL CL2015002516A patent/CL2015002516A1/es unknown
- 2015-09-08 PH PH12015502001A patent/PH12015502001A1/en unknown
- 2015-10-05 CR CR20150519A patent/CR20150519A/es unknown
- 2015-11-04 US US14/932,787 patent/US9611261B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105164121A (zh) | 2015-12-16 |
| WO2014138484A1 (en) | 2014-09-12 |
| MX374512B (es) | 2025-03-06 |
| HK1217486A1 (zh) | 2017-01-13 |
| BR112015021336A2 (pt) | 2017-07-18 |
| CL2015002516A1 (es) | 2016-03-28 |
| AU2014225604A1 (en) | 2015-09-10 |
| MX2015011618A (es) | 2015-12-17 |
| PE20151794A1 (es) | 2015-12-03 |
| JP2016510758A (ja) | 2016-04-11 |
| EP2964644B1 (en) | 2018-12-26 |
| EA201591614A1 (ru) | 2015-12-30 |
| US20140275058A1 (en) | 2014-09-18 |
| US20160280695A1 (en) | 2016-09-29 |
| CR20150519A (es) | 2016-01-11 |
| TW201446760A (zh) | 2014-12-16 |
| IL240829A0 (en) | 2015-10-29 |
| TN2015000382A1 (en) | 2017-01-03 |
| US20150252011A1 (en) | 2015-09-10 |
| US9085576B2 (en) | 2015-07-21 |
| PH12015502001A1 (en) | 2016-01-11 |
| CA2903215A1 (en) | 2014-09-12 |
| AU2014225604B2 (en) | 2018-05-17 |
| AP2015008716A0 (en) | 2015-09-30 |
| KR20150124985A (ko) | 2015-11-06 |
| EP2964644A1 (en) | 2016-01-13 |
| US9611261B2 (en) | 2017-04-04 |
| SG11201507196WA (en) | 2015-10-29 |
| CA2903215C (en) | 2021-07-20 |
| UY35377A (es) | 2014-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6374889B2 (ja) | β−セクレターゼ阻害剤としての過フッ素化シクロプロピル縮合１，３−オキサジン−２−アミン化合物、及び使用方法 | |
| JP6389830B2 (ja) | ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法 | |
| US9556135B2 (en) | Amino-dihydrothiazine and amino-dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use | |
| US10246429B2 (en) | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | |
| JP6576433B2 (ja) | β−セクレターゼ阻害剤としてのシクロプロピル縮合チアジン−２−アミン化合物及び使用方法 | |
| US8921363B2 (en) | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | |
| JP7149271B2 (ja) | β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法 | |
| JP2014526560A (ja) | β‐セクレターゼ調節因子としてのアミノオキサジン化合物およびアミノジヒドロチアジン化合物および使用方法 | |
| JP7177773B2 (ja) | β－セクレターゼ阻害剤としてのオキサジン誘導体および使用方法 | |
| US9309263B2 (en) | Fused multi-cyclic sulfone compounds as inhibitors of beta-secretase and methods of use thereof | |
| US8822485B2 (en) | Amino heteroaryl compounds as beta-secretase modulators and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170302 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170302 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171221 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180615 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180710 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180720 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6374889 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |